• Veradermics scheduled an investor call and webcast for July 15, 2026 at 8:00 a.m. ET to review Phase 2 Study 207 results.
• Update covers female treatment arms for VDPHL01, an extended-release oral minoxidil tablet, in mild-to-moderate pattern hair loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714064893) on July 14, 2026, and is solely responsible for the information contained therein.